NFKB1 and adult T-cell leukemia/lymphoma: In fact, many therapeutic approaches have been tested by targeting the NF-κB signaling pathway, such as rituximab in combination with ibrutinib, thalidomide, or lenalidomide in MCL [96] or the small interfering RNA (siRNA) nanotherapy in ATLL [97].